Abstract
The loss of insulin-secreting β cells is characteristic among type I and type II diabetes. Stimulating proliferation to expand sources of β cells for transplantation remains a challenge because adult β cells do not proliferate readily. The cell cycle inhibitor p57 has been shown to control cell division in human β cells. Expression of p57 is regulated by the DNA methylation status of the imprinting control region 2 (ICR2), which is commonly hypomethylated in Beckwith-Wiedemann syndrome patients who exhibit massive β cell proliferation. We hypothesized that targeted demethylation of the ICR2 using a transcription activator-like effector protein fused to the catalytic domain of TET1 (ICR2-TET1) would repress p57 expression and promote cell proliferation. We report here that overexpression of ICR2-TET1 in human fibroblasts reduces p57 expression levels and increases proliferation. Furthermore, human islets overexpressing ICR2-TET1 exhibit repression of p57 with concomitant upregulation of Ki-67 while maintaining glucose-sensing functionality. When transplanted into diabetic, immunodeficient mice, the epigenetically edited islets show increased β cell replication compared with control islets. These findings demonstrate that epigenetic editing is a promising tool for inducing β cell proliferation, which may one day alleviate the scarcity of transplantable β cells for the treatment of diabetes.
Original language | English |
---|---|
Article number | CI99170 |
Journal | Journal of Clinical Investigation |
Volume | 129 |
Issue number | 1 |
DOIs | |
State | Published - 2 Jan 2019 |
Bibliographical note
Funding Information:We would like to thank the Kaestner lab for helpful suggestions and discussions. This work was funded by the National Heart, Lung, and Blood Institute (NHLBI) grant 2T32HL007954-16 (to KO), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grants U01-DK089529 and R01-DK088383 (to KHK). This research was performed using resources and/or funding provided by the NIDDK-supported Human Islet Research Network (HIRN, RRID:SCR_014393; https://hirnetwork.org; UC4 DK104119) to KHK, DA, and BG. We acknowledge support of the Islet Cell Biology Core and Functional Genomics Core of Penn’s Diabetes Research Center (P30-DK019525).
Publisher Copyright:
© 2019 American Society for Clinical Investigation. All rights reserved.